Vera Therapeutics (NASDAQ:VERA) Price Target Raised to $64.00

Vera Therapeutics (NASDAQ:VERA) had its target price increased by Guggenheim from $56.00 to $64.00 in a research report released on Monday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

A number of other equities research analysts also recently weighed in on VERA. Evercore ISI raised Vera Therapeutics to a “strong-buy” rating in a research note on Monday, September 16th. Scotiabank initiated coverage on Vera Therapeutics in a research note on Wednesday, October 16th. They set a “sector outperform” rating and a $60.00 price target for the company. JPMorgan Chase & Co. raised their price target on Vera Therapeutics from $62.00 to $72.00 and gave the stock an “overweight” rating in a research note on Tuesday, September 3rd. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $107.00 price target on shares of Vera Therapeutics in a research note on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating, seven have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and a consensus target price of $53.56.

Vera Therapeutics Stock Down 5.4 %

Shares of Vera Therapeutics stock opened at $40.64 on Monday. The stock has a 50-day moving average price of $40.41 and a 200 day moving average price of $38.91. The company has a market cap of $2.23 billion, a P/E ratio of -18.39 and a beta of 1.00. The company has a current ratio of 21.43, a quick ratio of 21.43 and a debt-to-equity ratio of 0.15. Vera Therapeutics has a 1 year low of $9.68 and a 1 year high of $50.78.

Vera Therapeutics (NASDAQ:VERA) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.62) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.06). As a group, analysts expect that Vera Therapeutics will post -2.57 EPS for the current fiscal year.

Insider Buying and Selling at Vera Therapeutics

In other Vera Therapeutics news, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The stock was sold at an average price of $48.03, for a total value of $720,450.00. Following the sale, the director now owns 131,553 shares of the company’s stock, valued at $6,318,490.59. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. In other Vera Therapeutics news, CEO Marshall Fordyce sold 19,375 shares of the firm’s stock in a transaction that occurred on Wednesday, October 23rd. The stock was sold at an average price of $40.39, for a total value of $782,556.25. Following the sale, the chief executive officer now owns 307,972 shares of the company’s stock, valued at $12,438,989.08. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, Director Beth C. Seidenberg sold 15,000 shares of the firm’s stock in a transaction that occurred on Monday, October 28th. The shares were sold at an average price of $48.03, for a total value of $720,450.00. Following the completion of the sale, the director now directly owns 131,553 shares in the company, valued at $6,318,490.59. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 104,398 shares of company stock valued at $4,376,163 in the last 90 days. 21.70% of the stock is currently owned by insiders.

Institutional Trading of Vera Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaCentric Advisors LLC acquired a new stake in shares of Vera Therapeutics during the 3rd quarter worth approximately $332,000. China Universal Asset Management Co. Ltd. grew its holdings in shares of Vera Therapeutics by 64.1% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,545 shares of the company’s stock worth $466,000 after purchasing an additional 4,118 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Vera Therapeutics by 21.4% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,983 shares of the company’s stock worth $86,000 after purchasing an additional 350 shares in the last quarter. Eastern Bank acquired a new stake in shares of Vera Therapeutics during the 3rd quarter worth approximately $2,477,000. Finally, Handelsbanken Fonder AB grew its holdings in shares of Vera Therapeutics by 19.0% during the 3rd quarter. Handelsbanken Fonder AB now owns 13,800 shares of the company’s stock worth $610,000 after purchasing an additional 2,200 shares in the last quarter. Institutional investors and hedge funds own 99.21% of the company’s stock.

Vera Therapeutics Company Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.